Coronary artery aneurysm (CAA) is defined as a localized vascular dilation ≥1.5 times the diameter of the normal adjacent reference segment, found in up to 5% of patients undergoing coronary angiography. [1-3] Most are clinically silent and discovered incidentally, but complications include thrombosis, myocardial infarction, and rarely rupture with cardiac tamponade. [1][4]
The following figure illustrates the morphological spectrum and clinical presentations of aneurysmal coronary artery disease:
1. History
- Chest pain characterization: exertional angina, rest pain, or ACS-type symptoms (pressure, radiation, diaphoresis)
- Palpitations — may be the presenting complaint [5]
- Timing and progression: acute onset (thrombosis/embolization) vs. chronic exertional symptoms
- Prior cardiac history: previous MI, PCI, CABG, stent placement (iatrogenic CAA can develop post-intervention) [1]
- Childhood illness: history of Kawasaki disease (most common cause in children; late sequelae in adults) [4][6]
- Cocaine use: documented cause of CAA via episodic hypertension and endothelial damage [1][4]
- Connective tissue disorder symptoms: joint hypermobility, lens subluxation, skin findings (Marfan, Ehlers-Danlos) [1]
- Important negatives: absence of chest pain, syncope, dyspnea, or prior febrile childhood illness
2. Alarm Features
- Acute coronary syndrome (STEMI/NSTEMI) from in-situ thrombosis or distal embolization [1]
- Sudden cardiac death — particularly with giant aneurysms (>20 mm or >4× reference diameter) [5-6]
- Cardiac tamponade from aneurysm rupture (rare but catastrophic) [1][4]
- Rapidly expanding aneurysm — failure to escalate antithrombotic therapy is the most important contributor to sudden cardiovascular events [6]
- New heart failure symptoms suggesting ventricular dysfunction from silent MI
- Compression of adjacent structures from massive enlargement [1]
3. Medications
- Antiplatelet therapy: Low-dose aspirin is the mainstay for all CAA patients; dual antiplatelet therapy (aspirin + clopidogrel) for moderate-sized aneurysms [6-7]
- Anticoagulation: Warfarin (INR 2.0–3.0) or LMWH added for large/giant aneurysms (Z-score ≥10 or ≥8 mm); DOACs are emerging as alternatives, particularly in pediatric Kawasaki patients [8-9]
- GP IIb/IIIa inhibitors: Used during PCI for ACS with high thrombus burden [1][3]
- Avoid NSAIDs (ibuprofen) in patients on aspirin for thromboprophylaxis — interferes with antiplatelet effect of aspirin [6]
- Statins: Standard for atherosclerotic CAA; emerging data suggest benefit in Kawasaki-related CAA [8]
- Beta-blockers: May be considered empirically, particularly in patients with prior giant aneurysms [6]
- Contraindicated: Thrombolytics should be used with extreme caution given risk of aneurysm rupture
4. Diet
- Heart-healthy diet for atherosclerotic CAA (Mediterranean-style, low saturated fat)
- Vitamin K consistency if on warfarin
- Avoid cocaine and stimulants — documented cause of CAA via dynamic wall stress and endothelial damage [1][4]
- Hydration: Adequate hydration to reduce thrombotic risk, especially in patients with large aneurysms and flow stasis
5. Review of Systems
- Cardiovascular: chest pain, dyspnea on exertion, palpitations, syncope/presyncope, orthopnea
- Neurologic: focal deficits (embolic events)
- Musculoskeletal: joint hypermobility, habitus (connective tissue disorders)
- Dermatologic: rash history (Kawasaki), skin hyperextensibility
- Ophthalmologic: lens subluxation (Marfan)
- Vascular: claudication, known aortic aneurysm or peripheral aneurysms (10% of CAA patients have concurrent noncoronary aneurysms) [10]
- Infectious: febrile illness, endocarditis symptoms (mycotic aneurysm) [4]
6. Collateral History and Family History
- Childhood febrile illness with rash, conjunctivitis, lymphadenopathy (undiagnosed Kawasaki disease)
- Family history of aneurysmal disease (aortic, peripheral), connective tissue disorders (Marfan, Ehlers-Danlos), or sudden cardiac death
- Autoimmune disease in family: SLE, Takayasu arteritis, polyarteritis nodosa
- Social history: cocaine/stimulant use, IV drug use (mycotic aneurysm risk)
7. Risk Factors
- Atherosclerosis — most common cause in adults (aOR 7.97 for coronary atherosclerosis) [11]
- Kawasaki disease — most common cause in children [4]
- Hypertension (aOR 2.09), dyslipidemia (aOR 2.48), diabetes (aOR 1.51) [11]
- Aortic dissection (aOR 6.76) and aortic aneurysm (aOR 5.82) [11]
- Systemic lupus erythematosus (aOR 4.09) [11]
- Iatrogenic: post-PCI (balloon angioplasty, stenting, atherectomy, brachytherapy) [1]
- Connective tissue disorders: Marfan syndrome, Ehlers-Danlos [1]
- Vasculitis: Takayasu, polyarteritis nodosa, Behçet disease [1]
- Infectious: bacterial, syphilitic, mycobacterial, fungal (mycotic aneurysm) [1][4]
- Cocaine use [4]
- Male sex (78.5% in CAAR registry), mean age 65 years [2]
8. Differential Diagnosis
- Coronary artery ectasia (diffuse dilation without focal aneurysm — distinguished by extent)
- Coronary pseudoaneurysm (contained rupture with disrupted media — IVUS helps differentiate) [1]
- Spontaneous coronary artery dissection (SCAD) — can mimic or coexist
- Atherosclerotic plaque rupture with aneurysmal appearance from adjacent stenosis [1]
- Coronary artery fistula — may coexist with CAA
- Aortic root aneurysm with coronary involvement
- Takotsubo cardiomyopathy (if presenting with ACS-like symptoms)
- Cannot-miss: STEMI from thrombosed CAA, rupture with tamponade, mycotic aneurysm with sepsis
9. Past Medical History
- Prior Kawasaki disease (even remote/undiagnosed childhood illness)
- Known coronary artery disease, prior MI, PCI, or CABG
- Prior PCI/stenting — iatrogenic CAA can develop post-intervention [1]
- Connective tissue disorders, vasculitis, autoimmune disease
- Aortic or peripheral aneurysmal disease (strong association) [10-11]
- Chronic kidney disease, peripheral artery disease (predictors of MACE) [10]
- History of endocarditis or systemic infection
10. Physical Exam
- Vital signs: Hypotension/tachycardia (rupture, ACS, tamponade); hypertension (risk factor)
- Cardiac: New murmur (fistula), muffled heart sounds (tamponade), S3/S4 (heart failure)
- JVD and pulsus paradoxus if tamponade
- Peripheral pulses: Assess for peripheral aneurysms (popliteal, femoral) and peripheral artery disease
- Marfanoid habitus: Tall stature, arachnodactyly, pectus deformity, high-arched palate
- Skin: Hyperextensibility (Ehlers-Danlos), malar rash (SLE), track marks (IVDU/mycotic)
- Abdominal exam: Pulsatile mass (AAA)
- Exam is often unremarkable in asymptomatic incidentally discovered CAA
11. Lab Studies
- Troponin (serial): Rule out MI from thrombosis/embolization
- BNP/NT-proBNP: Assess for heart failure
- CBC: Thrombocytosis (Kawasaki), leukocytosis (infection/vasculitis)
- CRP/ESR: Elevated in vasculitis, Kawasaki, infectious etiologies
- Lipid panel: Atherosclerotic risk assessment
- HbA1c, BMP: Diabetes, renal function (CKD is a MACE predictor) [10]
- ANA, anti-dsDNA, complement: If SLE suspected [11]
- Blood cultures: If mycotic aneurysm suspected
- Coagulation studies: INR if on warfarin; anti-Xa levels if on LMWH [6]
- Urine drug screen: Cocaine
12. Imaging
- Coronary angiography: Most common diagnostic modality; remains the reference standard. Forceful, prolonged injection may be needed to avoid misinterpreting slow aneurysmal filling as thrombosis [1]
- CT coronary angiography (CTA): Excellent for evaluating coronary anatomy, aneurysm morphology, mural thrombus, and spatial relationships. First-line noninvasive modality, especially useful in Kawasaki follow-up [4][12]
- Transthoracic echocardiography: Initial screening, especially in children; assesses ventricular function and proximal coronary arteries [4]
- Cardiac MRI/MRA: Alternative for serial follow-up without radiation; evaluates myocardial viability and aneurysm morphology [4]
- IVUS: Provides superior delineation of vessel wall structures; distinguishes true aneurysm from pseudoaneurysm; aids stent sizing [1]
- OCT: Limited by small scan diameter in large aneurysms [1]
- Imaging of aorta and peripheral arteries should be considered given ~10% prevalence of concurrent noncoronary aneurysms [10]
13. Special Tests
- IVUS: Gold standard for distinguishing true aneurysm vs. pseudoaneurysm vs. plaque rupture with aneurysmal appearance [1]
- Fractional flow reserve (FFR): May assess functional significance of associated stenosis, though unproven in this specific setting [12]
- Stress testing: Exercise or pharmacologic stress to evaluate for inducible ischemia, particularly in chronic CAA management [6]
- Coronary artery Z-scores (pediatric/Kawasaki): Standardized classification of aneurysm severity [6]
14. ECG
- Baseline ECG in all patients
- ST-segment elevation or depression: Suggests acute thrombosis or ischemia
- Q waves: Prior silent MI (especially in Kawasaki patients — MIs in young children may be silent) [6]
- T-wave inversions: Ischemia or prior infarction
- Arrhythmias: Ventricular tachycardia/fibrillation from ischemic substrate
- New changes in ventricular function or ECG findings should heighten suspicion for coronary artery thrombosis [6]
15. Assessment
Classification: [1]
- Morphology: Saccular (focal outpouching) vs. fusiform (diffuse dilation) vs. giant (>20 mm or >4× reference diameter)
- Pathology: Atherosclerotic (most common in adults), inflammatory (Kawasaki, vasculitis), noninflammatory (congenital, connective tissue)
- True aneurysm (all 3 vessel wall layers involved) vs. pseudoaneurysm (contained rupture)
Severity stratification
- Small/medium CAA: Generally lower thrombotic risk; aspirin ± second antiplatelet agent
- Large/giant CAA: High thrombotic risk; requires antiplatelet + anticoagulation [6][9]
- Concomitant obstructive CAD is present in the majority and drives long-term prognosis [10]
Prognosis: The CAAR registry (1,729 patients, median follow-up 44.8 months) demonstrated a 22% mortality rate, with MACE driven primarily by underlying atherosclerotic burden rather than aneurysm-specific complications. Local aneurysm complications (rupture, thrombosis) were infrequent (~2%). [10]
The following central illustration from the CAAR registry summarizes key clinical features and predictors of adverse outcomes:
16. Treatment Plan
Medical therapy (all patients): [1][6-7]
- Antiplatelet: Low-dose aspirin for all; add clopidogrel for moderate aneurysms
- Anticoagulation: Warfarin (INR 2.0–3.0) or LMWH for large/giant aneurysms; DOACs emerging as alternatives [8]
- Statins, antihypertensives, diabetes management for atherosclerotic risk reduction
- Aggressive cardiovascular risk factor modification
Percutaneous intervention: [1][3]
- ACS with CAA culprit: Priority is restoring flow; thrombectomy (aspiration/mechanical) + GP IIb/IIIa inhibitors; high risk of no-reflow and distal embolization
- Saccular aneurysms not involving a side branch → covered stent exclusion
- Aneurysms involving a side branch → balloon/stent-assisted coil embolization
- If artery >5.5–6 mm, peripheral stents may be needed; 7F guiding catheter recommended [3]
Surgical intervention: [1]
- First-line for: Left main CAA, multiple/giant CAAs, saphenous vein graft aneurysms
- CABG with exclusion/ligation of the aneurysm
- Surgical patients more likely to have giant aneurysms, triple-vessel disease, diabetes [10]
17. Disposition
Admission criteria
- ACS presentation (STEMI/NSTEMI)
- Hemodynamic instability, tamponade, or suspected rupture
- Rapidly expanding aneurysm on serial imaging
- New heart failure or ventricular dysfunction
- Giant aneurysm with evidence of thrombosis
Observation indications
- Symptomatic patients with stable hemodynamics pending further workup
- Post-PCI monitoring (extended observation given higher complication rates)
Discharge criteria
- Asymptomatic, incidentally discovered CAA with stable imaging
- Appropriate antithrombotic therapy initiated
- Outpatient cardiology follow-up arranged
Specialist consultation triggers
- Interventional cardiology: All symptomatic CAA, ACS with aneurysmal culprit
- Cardiothoracic surgery: Left main, giant, or multiple CAAs
- Rheumatology: Suspected vasculitis or connective tissue disorder
- Pediatric cardiology/Kawasaki expert: Pediatric cases or adults with Kawasaki sequelae [8]
18. Follow Up / Return Precautions
Follow-up timing
- Kawasaki-related CAA: Lifelong follow-up with quantitative assessment of luminal dimensions [7]
- Atherosclerotic CAA: Serial imaging (CTA or angiography) at intervals guided by aneurysm size and symptoms; no established surveillance protocol exists
- Post-intervention: Close follow-up for stent thrombosis, restenosis, or aneurysm recurrence
- INR monitoring if on warfarin; anti-Xa levels if on LMWH [6]
Return precautions — seek immediate care for
- New or worsening chest pain, dyspnea, or syncope
- Signs of bleeding (if on anticoagulation): hematemesis, melena, severe bruising, headache
- Palpitations or lightheadedness
Patient counseling
- Strict medication adherence (antiplatelet/anticoagulant therapy)
- Avoid contact sports or high-injury-risk activities if on dual antiplatelet or anticoagulation therapy [6]
- Cocaine and stimulant avoidance
- Cardiovascular risk factor optimization
- Women of childbearing age: pregnancy should be supervised by a multidisciplinary team; avoid oral contraceptives that increase thrombosis risk [6]
References
1. Management of Coronary Artery Aneurysms. — Kawsara A, Núñez Gil IJ, Alqahtani F, et al. JACC. Cardiovascular Interventions. 2018.
2. Coronary Artery Aneurysms, Insights From the International Coronary Artery Aneurysm Registry (CAAR). — Núñez-Gil IJ, Cerrato E, Bollati M, et al. International Journal of Cardiology. 2020.
3. SCAI Expert Consensus Statement on the Management of Patients With STEMI Referred for Primary PCI. — Tamis-Holland JE, Abbott JD, Al-Azizi K, et al. Journal of the Society for Cardiovascular Angiography & Interventions. 2024.
4. Spectrum of Coronary Artery Aneurysms: From the Radiologic Pathology Archives. — Jeudy J, White CS, Kligerman SJ, et al. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 2018.
5. Coronary Artery Aneurysms: A Clinical Case Report and Literature Review Supporting Therapeutic Choices. — Sannino M, Nicolai M, Infusino F, et al. Journal of Clinical Medicine. 2024.
6. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. — McCrindle BW, Rowley AH, Newburger JW, et al. Circulation. 2017.
7. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. — Virani SS, Newby LK, Arnold SV, et al. Journal of the American College of Cardiology. 2023.
8. Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association. — Jone PN, Tremoulet A, Choueiter N, et al. Circulation. 2024.
9. Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease: A Scientific Statement From the American Heart Association. — Giglia TM, Massicotte MP, Tweddell JS, et al. Circulation. 2013.
10. Long-Term Prognosis of Coronary Aneurysms: Insights of CAAR, an International Registry. — Sánchez-Sánchez I, Cerrato E, Bollati M, et al. JACC. Cardiovascular Interventions. 2024.
11. Epidemiology and Risk Factors of Coronary Artery Aneurysm in Taiwan: A Population Based Case Control Study. — Fang CT, Fang YP, Huang YB, Kuo CC, Chen CY. BMJ Open. 2017.
12. ACR Appropriateness Criteria® Congenital or Acquired Heart Disease. — Krishnamurthy R, Suman G, Chan SS, et al. Journal of the American College of Radiology : JACR. 2023.